Hall Private Wealth Advisors Regeneron Pharmaceuticals, Inc. Transaction History

Hall Private Wealth Advisors

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 18, 2023	SELL	$680.49 - $826.97 $137,458 - $167,047	-202 Reduced 22.27%	705 $579,000
Q4 2022 Jan 20, 2023	SELL	$705.89 - $766.39 $5.11 Million - $5.54 Million	-7,233 Reduced 88.86%	907 $0
Q3 2022 Oct 31, 2022	BUY	$573.97 - $724.32 $66,006 - $83,296	115 Added 1.43%	8,140 $5.61 Million
Q2 2022 Jul 20, 2022	SELL	$548.35 - $738.84 $1.45 Million - $1.95 Million	-2,637 Reduced 24.73%	8,025 $4.74 Million
Q1 2022 May 02, 2022	BUY	$595.12 - $698.43 $147,589 - $173,210	248 Added 2.38%	10,662 $7.45 Million
Q4 2021 Jan 28, 2022	BUY	$543.48 - $670.97 $34,782 - $42,942	64 Added 0.62%	10,414 $6.58 Million
Q3 2021 Nov 12, 2021	BUY	$574.03 - $680.96 $373,693 - $443,304	651 Added 6.71%	10,350 $6.26 Million
Q2 2021 Aug 16, 2021	BUY	$472.8 - $558.54 $3.67 Million - $4.33 Million	7,759 Added 399.95%	9,699 $5.42 Million
Q4 2020 Mar 11, 2021	BUY	$478.3 - $607.98 $927,902 - $1.18 Million	1,940 New	1,940 $937,000

1,534

83.6M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $76.7B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Hall Private Wealth Advisors, based on Form 13F filings with the SEC.

Stay updated on Hall Private Wealth Advisors with notifications on news.